Product-Market Fit for Healthtech Startups

TL;DR: Product-market fit for healthtech is when customers are desperately willing to adopt your solution despite regulatory complexity, incomplete features, and long sales cycles. In regulated industries, PMF signals include customers deploying across multiple use cases, referral-driven growth exceeding 80%, and teams requesting the product after leaving organizations. Unlike consumer software, healthtech PMF requires 6-12 months of upfront user research, but founders who execute this earn customers' deep trust and achieve 20%+ monthly growth post-launch.

Context: Why Product-Market Fit in Healthtech Looks Different

After interviewing 200+ founders on the PMF Show, one pattern emerged across regulated industries like healthtech, fintech, and enterprise legal: product-market fit is harder to reach, but far stronger once achieved. Healthtech founders face unique constraints—clinical validation, compliance timelines, doctor skepticism, integration barriers with legacy hospital systems, and the weight of safety-critical decision making. Yet the founders who nailed product-market fit for healthtech did so by understanding that PMF in regulated spaces isn't about moving fast and breaking things. It's about moving deliberately and earning trust.

This is why healthtech PMF teaches broader lessons: if you can prove customers desperately need your solution despite regulatory friction, you've found something truly durable. That signal is stronger than viral adoption in a consumer app.

How Is Product-Market Fit Different in Regulated Industries?

In healthtech, PMF can't be measured by app downloads or engagement metrics alone. Regulated industries demand a fundamentally different proof point: customers must want your product so badly that they'll endure compliance overhead, integration pain, and organizational change to adopt it.

Helen Hastings, founder of Quanta, a fintech accounting platform, spent an entire year doing user research before writing a single line of product code. "We interviewed accountants, bookkeepers, finance teams," she recalled. This deep research wasn't optional—it was essential to understand whether the problem was worth solving at the regulatory complexity level. After launch, Quanta grew 20% month-over-month, a signal that validated her upfront investment. The research phase wasn't a delay; it was the foundation of PMF.

"You have to talk to your customers obsessively before you build. In fintech and regulated spaces, you can't afford to build the wrong thing." — Helen Hastings, Quanta

According to Helen, PMF in regulated industries is signaled not by early adoption rates, but by the depth of early customer commitment. A fintech startup with 10 customers who are deeply embedded and expanding usage is further along than one with 100 casual users.

Key stat: Quanta achieved 20% MoM growth after launch, enabled by a year of pre-launch user research and validation.

What Does Early PMF Look Like in Healthtech?

The strongest PMF signal in healthtech is customer expansion and organic word-of-mouth, often exceeding 80% of new business. This happens because customers in regulated industries make considered purchasing decisions and trust recommendations from peers.

Omar Haroun, founder of Eudia (AI for enterprise legal teams), hit $1 million ARR in approximately six months—but 90% of that revenue came from customer referrals. No paid ads. No growth hacking. Customers were so satisfied with Eudia's solution that they actively recommended it to competing law firms and in-house legal teams. This referral density is a telltale sign of deep PMF in regulated industries.

When asked how he defined PMF, Omar gave a definition that resonates across healthtech: "What can you uniquely provide that your customer is desperate for?"

"PMF is when you're uniquely solving a problem your customers are desperate to fix. If 90% of your growth is referrals, you've found it." — Omar Haroun, Eudia

Desperation is the key word. In consumer software, PMF means customers prefer your solution. In regulated industries like healthtech and legal, PMF means customers need your solution so badly that they'll champion it internally and refer competitors. Omar's 90% referral rate is not a marketing win—it's a PMF signal.

According to Omar's experience, this happens when you're solving a problem that's been painful for 5+ years and no one else has solved it properly. Healthtech founders should ask: Are hospital teams or clinician groups desperate for our solution? Are they actively referring us?

Key stat: Eudia achieved $1M ARR in ~6 months with 90% of revenue from customer referrals, indicating strong product-market fit in a regulated B2B segment.

Can You Sell Healthtech Products Before They're Built?

Conventional startup wisdom says: build first, sell second. But in healthtech and enterprise software, this is backwards. Strong product-market fit can be validated before you write production code—if you know how to listen to customers and show them what you're building.

Yogi Goel, founder of Maxima (an agentic platform for enterprise accounting), sold customers on Figma prototypes before the product existed. Yogi would design the user experience, show it to accounting teams, get feedback, refine the design, and iterate—all before committing engineering resources. This approach is deeply aligned with how healthtech companies should operate. Clinical teams are more likely to engage with mockups and prototypes than provide feedback on raw code.

Yogi's most important signal came in summer 2025, when he felt the team had hit PMF. "We started landing enterprise customers even though our product was incomplete," Yogi said. The fact that customers would sign and implement Maxima despite missing features was the clearest proof that they were desperate for the solution.

"You can sell healthtech and enterprise software on prototypes. Customers will tell you what matters. If they're willing to deal with incomplete features, you've found PMF." — Yogi Goel, Maxima

This directly challenges the "move fast" narrative. By slowing down to validate via prototypes, Yogi de-risked the entire company. He learned which features actually mattered to customers before his team spent three months building the wrong thing. In healthtech, this approach is particularly valuable because clinical workflows are nuanced, and understanding them before building saves months of rework.

Key stat: Maxima landed enterprise customers with incomplete features, a signal that customers' desperation for the solution exceeded their demand for feature completeness—a hallmark of strong PMF in regulated industries.

What Are the Strongest PMF Signals in Healthtech?

Beyond referrals and willingness to adopt early, there are specific behavioral signals that indicate true PMF in regulated industries. These signals often involve expansion and persistence—metrics that require deeper customer commitment than casual app usage.

Bhaskar Sunkara, previously co-founder of AppDynamics (acquired by Cisco for $3.7B), has deep experience recognizing PMF in regulated B2B software. When he launched Bicycle AI, he looked for a specific pattern: customers who deployed the product in one use case and then wanted it in all their others.

"The PMF signal was when one team started using our product and then other teams within the same organization wanted it," Bhaskar explained. This cross-functional demand is powerful because it indicates the product is solving a problem that transcends a single department or workflow. In healthtech, this might look like a hospital system adopting your diagnostic tool in cardiology, then requesting it in oncology, then radiology.

Another signal Bhaskar observed: persistence beyond employment. People who left companies that used Bicycle AI would ask their new employers to adopt it. This is the highest form of product affinity—customers are loyal to the product, not just the company they work for. In healthtech, this translates to clinicians bringing their preferred digital tools with them as they change hospitals or practices.

"PMF is when customers deploy on one use case and then want it everywhere. And when people who leave still request the product at their new company." — Bhaskar Sunkara, Bicycle AI

According to Bhaskar's experience, this expansion-and-persistence pattern emerges when the product solves a problem that's existential to the customer's workflow. In healthtech, identifying that existential problem requires deep customer research—exactly what Helen Hastings invested a year doing.

Key stat: AppDynamics, which Bhaskar co-founded, was acquired by Cisco for $3.7B—a valuation that was possible because of the company's penetration across multiple customer use cases and industries, a direct result of capturing strong PMF signals early.

Key Takeaways: Finding Product-Market Fit in Healthtech

1. Invest in pre-launch research. Helen Hastings spent a year interviewing users before building Quanta. This wasn't wasted time—it was the foundation of her 20% MoM post-launch growth. In healthtech, one year of research is often more valuable than six months of shipping and learning.

2. Define PMF as customer desperation, not just preference. Omar Haroun's 90% referral rate came from solving a problem customers were desperate to fix. Healthtech PMF isn't about nice-to-have features; it's about solving acute pain that's been unsolved for years.

3. Validate with prototypes before building. Yogi Goel sold Maxima on Figma designs before writing production code. In healthtech, clinical teams will engage thoughtfully with mockups and mockups reveal what actually matters to them.

4. Look for expansion as a PMF signal. When customers want to deploy your product across multiple departments or use cases (Bhaskar's signal), you've found something durable. In healthtech, this might be one hospital unit requesting your solution, then another.

5. Measure referrals, not just customer acquisition. Eudia's 90% referral-driven growth in six months is a stronger PMF signal than any paid customer acquisition. In regulated spaces, word-of-mouth is the highest compliment.

6. Watch for persistence beyond the sale. If customers request your product after changing jobs (Bhaskar's second signal), you've built something with deep loyalty. In healthtech, this means clinicians and administrators are attached to your solution, not just their current employer's mandate.

7. Remember: incomplete products can indicate strong PMF. Maxima landing enterprise customers despite missing features shows customers are solving a more urgent problem than the missing features. Don't confuse a feature-complete product with market fit.

FAQ: Common Questions About Product-Market Fit for Healthtech

Q: How long should we spend on user research before building a healthtech product?

A: Helen Hastings spent an entire year interviewing accountants and finance teams before building Quanta. For healthtech, expect 6-12 months of upfront research, especially if you're working across hospital systems or clinical practices. This research isn't a cost—it's the foundation of PMF.

Q: What's the difference between product-market fit for healthtech vs. consumer apps?

A: In consumer apps, PMF is signaled by engagement and retention. In healthtech, PMF is signaled by customer desperation, referrals (80%+ of growth), and cross-functional expansion. Healthtech PMF is stronger but slower to achieve.

Q: Can we sell a healthtech product before it's fully built?

A: Yes. Yogi Goel sold Maxima on Figma prototypes before the product existed. Showing clinical teams and hospital administrators your vision via mockups and prototypes is more efficient than building and iterating. This is especially true in healthtech, where workflows are complex and customer input is essential.

Q: What's the clearest sign we've achieved product-market fit in healthtech?

A: Multiple signals together indicate PMF: (1) customers expanding across multiple use cases or departments, (2) referral-driven growth exceeding 80%, (3) customers requesting the product after changing jobs, and (4) willingness to adopt despite regulatory complexity or incomplete features. One signal alone isn't enough; you're looking for a constellation.

Q: Does 20% month-over-month growth mean we have product-market fit?

A: In healthtech, 20% MoM growth (like Quanta achieved) is a strong signal, especially when it's driven by deep customer commitment and referrals rather than paid acquisition. But growth rate alone isn't the measure—the quality of that growth (expansion, referrals, persistence) matters more.

Sources: Listen to the Full Founder Stories

• Helen Hastings, Quanta (S5) — Fintech accounting platform. Year-long user research phase, 20% MoM growth post-launch. Discussed on PMF Show Season 5.

• Omar Haroun, Eudia (S5) — AI for enterprise legal teams. $1M ARR in ~6 months, 90% referral-driven growth. Discussed on PMF Show Season 5.

• Yogi Goel, Maxima (S5) — Agentic platform for enterprise accounting. Sold on Figma prototypes, landed enterprise customers with incomplete features. Discussed on PMF Show Season 5.

• Bhaskar Sunkara, Bicycle AI (S5) — Previously co-founded AppDynamics (acquired by Cisco for $3.7B). Identified PMF signals: cross-functional expansion and persistence beyond employment. Discussed on PMF Show Season 5.